Nature's Sunshine Products Inc. Insider Trading

NATR

Last 12 months

Insiders sold $2.09M and bought nothing on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan. EVP & President, Europe Bryant J Yates sold 475K on Mar 13, 19% of their stake, outside a plan. The last open-market buy by an executive or director was in May 2016.

Net open-market

−$2.09M

0 buys · 11 sales

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

0 / 5

executives and directors

Last open-market buy

May 2016

May 31, 2016

Get an email when NATR's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Aug 17	Phil Frohlich Large holder	Bought	20,000	$14.69	294K	1.0%	Form 4
Aug 6 – 10	Prescott Group Capital Management, L.l.c. Large holder	Bought 13 parts	141,389	$16.40 average	$2.32M	7.9%	Form 4
Jun 12	Kevin R. Herbert EVP & President, North America	SoldNo plan 2 parts	2,000	$20.68 average	41K	3.9%	Form 4
Jun 5	Bryant J Yates EVP & President, Europe	SoldNo plan	11,968	$19.90	238K	13%	Form 4
Jun 1	Daniel C Norman EVP & President, Asia	SoldNo plan	9,713	$20.64	200K	17%	Form 4
May 21	Nathan G Brower EVP, General Counsel	SoldNo plan	12,015	$21.84	262K	22%	Form 4
Mar 13	Bryant J Yates EVP & President, Europe	SoldNo plan	19,516	$24.35	475K	19%	Form 4
Mar 13	Daniel C Norman EVP & President, Asia	SoldNo plan	15,383	$24.52	377K	23%	Form 4
Mar 13	Jonathan David Lanoy SVP, Chief Accounting Officer	SoldNo plan	4,000	$24.70	99K	7.9%	Form 4
Dec 12, 2025	Bryant J Yates EVP & President, Europe	SoldNo plan	1,700	$22.29	38K	1.7%	Form 4
Nov 18, 2025	Jonathan David Lanoy SVP, Chief Accounting Officer	SoldNo plan	5,000	$20.45	102K	9.8%	Form 4
Nov 14, 2025	Nathan G Brower EVP, General Counsel	SoldNo plan	3,800	$20.81	79K	7.5%	Form 4
Nov 12, 2025	Daniel C Norman EVP & President, Asia	SoldNo plan	8,884	$20.46	182K	12%	Form 4
Aug 26, 2025 – Aug 29, 2025	Bryant J Yates EVP & President, Europe	SoldNo plan 2 parts	9,672	$16.74 average	162K	9.0%	Form 4
Aug 13, 2025	Jonathan David Lanoy SVP, Chief Accounting Officer	SoldNo plan	5,000	$16.51	83K	9.1%	Form 4
Aug 13, 2025	Nathan G Brower EVP, General Counsel	SoldNo plan	9,996	$16.54	165K	17%	Form 4
Jun 27, 2025	Fosun Pharma USA Inc. Large holder	SoldNo plan	2,854,607	$11.46	$32.7M	98%	Form 4

Aug 17
Phil Frohlich
Large holder · bought 20,000 at $14.69
294K
1.0% of stake
Aug 6 – 10
Prescott Group Capital Management, L.l.c.
Large holder · bought 141,389 at avg $16.40
$2.32M
7.9% of stake
Jun 12No plan
Kevin R. Herbert
EVP & President, North America · sold 2,000 at avg $20.68
41K
3.9% of stake
Jun 5No plan
Bryant J Yates
EVP & President, Europe · sold 11,968 at $19.90
238K
13% of stake
Jun 1No plan
Daniel C Norman
EVP & President, Asia · sold 9,713 at $20.64
200K
17% of stake
May 21No plan
Nathan G Brower
EVP, General Counsel · sold 12,015 at $21.84
262K
22% of stake
Mar 13No plan
Bryant J Yates
EVP & President, Europe · sold 19,516 at $24.35
475K
19% of stake
Mar 13No plan
Daniel C Norman
EVP & President, Asia · sold 15,383 at $24.52
377K
23% of stake
Mar 13No plan
Jonathan David Lanoy
SVP, Chief Accounting Officer · sold 4,000 at $24.70
99K
7.9% of stake
Dec 12, 2025No plan
Bryant J Yates
EVP & President, Europe · sold 1,700 at $22.29
38K
1.7% of stake
Nov 18, 2025No plan
Jonathan David Lanoy
SVP, Chief Accounting Officer · sold 5,000 at $20.45
102K
9.8% of stake
Nov 14, 2025No plan
Nathan G Brower
EVP, General Counsel · sold 3,800 at $20.81
79K
7.5% of stake
Nov 12, 2025No plan
Daniel C Norman
EVP & President, Asia · sold 8,884 at $20.46
182K
12% of stake
Aug 26, 2025 – Aug 29, 2025No plan
Bryant J Yates
EVP & President, Europe · sold 9,672 at avg $16.74
162K
9.0% of stake
Aug 13, 2025No plan
Jonathan David Lanoy
SVP, Chief Accounting Officer · sold 5,000 at $16.51
83K
9.1% of stake
Aug 13, 2025No plan
Nathan G Brower
EVP, General Counsel · sold 9,996 at $16.54
165K
17% of stake
Jun 27, 2025No plan
Fosun Pharma USA Inc.
Large holder · sold 2,854,607 at $11.46
$32.7M
98% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch NATR, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with NATR

CompareIntrinsic value

ARQTArcutis Biotherapeutics Inc.

$34.05+6.41%65

ORGOOrganogenesis Holdings Inc.

$0.87+4.19%50

ARDXArdelyx Inc.

$3.27+7.92%40

ZLABZai Lab Ltd

$22.80+3.83%40

SVASernova Biotherapeutics Inc

No recent price0

INVAInnoviva Inc.

$21.26+1.58%56

HCMHUTCHMED (China) Ltd

$13.92+6.42%45

ESPREsperion Therapeutics Inc.

No recent price50

Held by ETFs

NATR is in 22 US ETFs. The largest of them, with NATR's weight in each:

Spot a number that looks wrong? Check it in NATR's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing NATR

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.